A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension.

Trial Profile

A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2013

At a glance

  • Drugs TBC 3711 (Primary)
  • Indications Hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jun 2011 Actual initiation date changed from Mar 2007 to Jan 2006 as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Planned end date changed from 1 Mar 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top